Ezetimibe (Zetia) and PPIs (Omeprazole, Pantoprazole): Drug Interaction Guide

What these drugs are

Ezetimibe (Zetia) is a cholesterol absorption inhibitor that blocks the NPC1L1 transporter in the intestinal wall, lowering the amount of dietary and biliary cholesterol absorbed into the bloodstream. It is FDA-approved alone or combined with a statin for lowering LDL cholesterol.

Proton pump inhibitors (PPIs) are a drug class that includes omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, and dexlansoprazole. They are FDA-approved for acid-related conditions such as GERD, erosive esophagitis, and peptic ulcer disease, and they work by irreversibly inhibiting the gastric H+/K+ ATPase.

These two drug classes are commonly prescribed together because dyslipidemia and acid-reflux disorders both become more common with age, and there is no formulation confusion risk between them, since neither has a sibling compound that shares a name or mechanism.

The core answer

Ezetimibe is metabolized mainly through intestinal and hepatic glucuronidation (a phase II pathway using UGT enzymes), not through the cytochrome P450 system. Omeprazole and most other PPIs are metabolized mainly through CYP2C19, with a smaller contribution from CYP3A4. Because these two clearance pathways do not overlap, there is no established pharmacokinetic mechanism by which a PPI would raise or lower ezetimibe blood levels, or vice versa. This conclusion follows from the separation of metabolic pathways and from the absence of either drug from the other's FDA-approved drug interaction labeling; it is not confirmed by a dedicated crossover pharmacokinetic study of ezetimibe combined specifically with omeprazole or pantoprazole, and readers with additional interacting medications, liver disease, or genetic variation in drug metabolism should still confirm their own regimen with a pharmacist.

Why the pathways don't overlap

Ezetimibe undergoes rapid conjugation in the gut wall and liver to form an active glucuronide metabolite, which recirculates through the enterohepatic system. This process does not depend on cytochrome P450 enzymes, and ezetimibe is not considered a clinically relevant substrate, inhibitor, or inducer of the major CYP enzymes at approved doses.

PPIs take the opposite route. Omeprazole and esomeprazole rely heavily on CYP2C19 for clearance, with people who carry reduced-function CYP2C19 variants (more common in East Asian populations than in populations of European ancestry) experiencing higher PPI blood levels. Pantoprazole also uses CYP2C19 but has an additional sulfotransferase step that makes its clearance somewhat less sensitive to CYP2C19 genotype. None of this metabolism touches the glucuronidation enzymes ezetimibe depends on.

PPIs also raise gastric pH for much of the day, which matters for drugs whose absorption depends on an acidic stomach (examples include ketoconazole and certain iron formulations). Ezetimibe's absorption has not been shown to depend on gastric pH in this way, so acid suppression is not expected to blunt its cholesterol-lowering effect.

Evidence-status assessment

The three-drug question: statin plus ezetimibe plus PPI

Most patients taking ezetimibe also take a statin, and many also take a PPI. The interaction that actually matters in this combination involves the statin and the PPI, not ezetimibe. Omeprazole is a weak CYP2C19 inhibitor, which is a minor clearance pathway for some statins. Atorvastatin (CYP3A4) and rosuvastatin (largely CYP2C9) are not expected to be materially affected by omeprazole through this route. Ezetimibe itself does not add to or subtract from this picture, since it does not share a metabolic pathway with either the statin or the PPI.

Anyone changing or adding a statin, a PPI, and ezetimibe at the same time should still have the full combination reviewed by a pharmacist or prescriber, because interaction risk in polypharmacy depends on the specific statin, the specific PPI, and any other medications on the list, not on ezetimibe alone.

Hepatic considerations: separate risks, not combined risk

Ezetimibe carries a labeled risk of liver enzyme elevation, and use in moderate to severe hepatic impairment (Child-Pugh B or C) combined with a statin is specifically cautioned against on the Zetia label. PPIs are generally considered safe in compensated liver disease, though caution is warranted in advanced cirrhosis. These are independent, drug-specific considerations. No published signal reviewed for this article suggests that combining ezetimibe with a PPI creates additive liver injury beyond what each drug carries on its own; this absence of a signal is not the same as a formal safety study designed to test the combination, so unexplained fatigue, jaundice, or dark urine in a patient taking either drug still warrants prompt evaluation.

Practical timing

There is no pharmacological basis identified for spacing ezetimibe and a PPI apart. Ezetimibe does not depend on stomach acid for absorption and can be taken with or without food. PPIs are typically taken 30 to 60 minutes before a meal for best acid suppression, but this timing is about the PPI's own efficacy, not about avoiding an interaction with ezetimibe. Patients can generally take both medications at whatever time fits their routine, including together in the morning.

Special populations

Renal impairment: Ezetimibe exposure can increase modestly in severe renal disease, but this is a property of ezetimibe alone and is not described as being compounded by PPI use.

Hepatic impairment: Each drug has its own hepatic caution, described above; the combination does not appear to add a new hepatic risk beyond those individual cautions.

CYP2C19 poor metabolizers: People with reduced CYP2C19 function, a genetic variant more common in some East Asian populations, will have higher PPI blood levels than typical metabolizers. Because ezetimibe does not rely on CYP2C19, this genetic variation is not expected to create a secondary interaction with ezetimibe.

Switching between PPIs

Omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, and dexlansoprazole all share CYP2C19-dominant metabolism and none are described in their labeling as UGT inhibitors. Based on this shared mechanism, switching among PPIs for formulary or tolerability reasons is not expected to change the ezetimibe relationship. Pantoprazole is sometimes preferred in patients on complex regimens because it has comparatively weaker CYP2C19 inhibitory activity, which can reduce interaction risk with other CYP2C19-dependent drugs such as clopidogrel; this consideration is unrelated to ezetimibe specifically.

When to contact a prescriber or pharmacist

• New or worsening muscle pain or weakness, particularly if a statin is also part of the regimen
• Diarrhea lasting more than two weeks on a PPI, which can reflect magnesium depletion or, rarely, Clostridioides difficile infection unrelated to ezetimibe
• Jaundice, dark urine, or unexplained fatigue, which warrant liver function testing regardless of which drug is suspected
• Starting cyclosporine, a fibrate (such as gemfibrozil), or cholestyramine, all of which have confirmed interactions with ezetimibe that are unrelated to PPI use
• Any new prescription added to an existing statin-ezetimibe-PPI regimen, since the safety of that specific combination depends on the new drug, not on the pair already in place

Evidence boundary

What is established: ezetimibe's clearance pathway (glucuronidation) and the PPI class's clearance pathway (mainly CYP2C19) do not overlap, and current FDA labeling for Zetia and for omeprazole does not list the other drug class as an interaction. What is plausible but not directly confirmed by a dedicated trial: that this mechanistic separation translates into no meaningful change in either drug's blood levels or clinical effect when co-administered in real patients. What is not established from the sources available for this review: any specific numeric comparison of LDL-lowering with and without concurrent PPI use. Readers should treat this article as a mechanism-and-label-based overview rather than a substitute for a pharmacist's review of a complete, individual medication list, and should ask their prescriber to confirm the current FDA label status of both drugs, since label content is periodically revised.